BCT History

Bio-Cancer Treatment International Limited (“BCT” or the “Company”) is a Hong Kong-based drug development company specializing in the research, development and marketing of novel therapeutics for the treatment of human malignancies, in particular hepatocellular carcinoma (HCC or liver cancer), and autoimmune diseases or immune system disorders such as multiple sclerosis (MS), rheumatoid arthritis (RA), and graft versus host disease (GVHD). The Company was founded in 2001 by Dr. Paul N.M. Cheng, a medical oncologist and hematologist, and Dr. Jun Sing Lee, a successful businessman. ...

Company News 　  BCT-100, Hong Kong’s First Novel Biologic Anti-cancer Drug, Granted IND fro... 26/6/2012  A Phase I study of the safety and preliminary efficacy of PEG-BCT-100 in pa... 23/4/2012  PEG-BCT-100(rhArgI-peg5000) IND application approved by FDA...... 15/3/2012 　    Product BCT-100 BCT-100 is a recombinant human arginase in phosphate buffer for intravenous injection use only. It is presently a drug under clinical studies and if approved, it will be indicated for the treatment of hepatocellular carcinoma, refractory myeloid leukemia, T cell Acute Lymphoblastic leukemia, and prostate cancers. Please contact us for details in formulation. 　 Methoxy poly(ethylene glycol) succinimidyl propionate (mPEG-SPA) mPEG-SPA MW 5,000 Dalton (AR grade) mPEG-SPA MW 5,000 Dalton (USP-compliant grade) mPEG-COOH MW 5,000 Dalton (AR grade) mPEG-COOH MW 5,000 Dalton (USP-compliant grade)